Myambutol (Ethambutol Hydrochloride)

Ethambutol Hydrochloride, the active ingredient in Myambutol, is an antitubercular (bacteriostatic antimycobacterial) presented as a tablet for oral use. It treats tuberculosis in adults and children under medical supervision.

GNH USA supplies Myambutol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ethambutol Hydrochloride is used as part of combination regimens for mycobacterial infections, primarily tuberculosis.

Pulmonary tuberculosis: contributes to bacterial growth inhibition as part of multi‑drug therapy. Extrapulmonary tuberculosis: aids in controlling infection in sites such as lymph nodes, pleura, or bone. Multidrug‑resistant tuberculosis (as part of a regimen): helps reduce bacterial load when combined with other active agents.

Ethambutol Hydrochloride may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Visual disturbances (blurred vision, color vision changes) - Rash or mild skin irritation - Nausea or vomiting - Peripheral neuropathy (tingling or numbness) - Elevated liver enzymes

Serious or Rare Side Effects: - Optic neuritis leading to permanent vision loss - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic failure or severe hepatitis - Acute interstitial nephritis - Anaphylaxis

When prescribing Ethambutol Hydrochloride, clinicians should consider several safety measures.

Monitor visual acuity: baseline and periodic eye examinations are essential. Assess renal function: dosage may need adjustment in renal impairment. Evaluate hepatic status: use cautiously in patients with liver disease. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Adjust dose in elderly patients: consider reduced renal clearance. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ethambutol Hydrochloride can interact with several other medications, influencing safety or efficacy.

Major Interactions (Avoid): - Isoniazid: increased risk of neurotoxicity. - Rifampicin: heightened incidence of optic neuritis. - Streptomycin: additive ototoxicity when used together.

Moderate Interactions (Monitor Closely): - Pyrazinamide: may enhance hepatotoxic potential. - Fluoroquinolones: monitor for overlapping neuro‑ophthalmic effects. - Antacids containing aluminum or magnesium: can reduce ethambutol absorption; separate administration by at least 2 hours.